Fujii S, Espenschied ST, Anand V, Bettencourt-Silva J, Han Y, Ito G, Koseki A, Kosugi A, Kozloski J, Matsumoto R, Meng S, Mulligan N, Musich RJ, Newhall KP, Oshina E, Sekiguchi S, Wang Y, Hu J, Ciorba M, Sibley LD, Okamoto R, Stappenbeck TS. Quantifying the fidelity of in vitro human cell culture systems using a biomedical foundation model. Proceedings of the National Academy of Sciences of the United States of America. 2026.03; 123 (12): e2520482123. ( PubMed, DOI )

Sakura Kirino, Kaoru Tsuchiya, Masayuki Kurosaki, Shun Kaneko, Kento Inada, Koji Yamashita, Leona Osawa, Yuka Hayakawa, Shuhei Sekiguchi, Mao Okada, Wan Wang, Mayu Higuchi, Kenta Takaura, Chiaki Maeyashiki, Nobuharu Tamaki, Yutaka Yasui, Hiroyuki Nakanishi, Jun Itakura, Yuka Takahashi, Yasuhiro Asahina, Namiki Izumi. Relative dose intensity over the first four weeks of lenvatinib therapy is a factor of favorable response and overall survival in patients with unresectable hepatocellular carcinoma. PLoS One. 2020; 15 (4): e0231828. ( PubMed, DOI )

Wan Wang, Kaoru Tsuchiya, Masayuki Kurosaki, Yutaka Yasui, Kento Inada, Sakura Kirino, Koji Yamashita, Shuhei Sekiguchi, Yuka Hayakawa, Leona Osawa, Mao Okada, Mayu Higuchi, Kenta Takaura, Chiaki Maeyashiki, Shun Kaneko, Nobuharu Tamaki, Hiroyuki Nakanishi, Jun Itakura, Yuka Takahashi, Yasuhiro Asahina, Nobuyuki Enomoto, Namiki Izumi. Sorafenib-Regorafenib Sequential Therapy in Japanese Patients with Unresectable Hepatocellular Carcinoma-Relative Dose Intensity and Post-Regorafenib Therapies in Real World Practice. Cancers (Basel). 2019.10; 11 (10): ( PubMed, DOI )